Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 3/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020310 | 0.81 | HRH3 (0.56) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL14922323 | 0.81 | HRH3 (0.66) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL1263730 | 0.81 | PTGES (0.68) | LTA4HKDM4EALDH1A1SMN1; SMN2APP | |
| SCHEMBL19958267 | 0.81 | APP (0.70) | KDM4EALDH1A1APP | |
| SCHEMBL1263098 | 0.81 | ALDH1A1 (0.62) | LTA4HKDM4EALDH1A1SMN1; SMN2APP | |
| SCHEMBL91406 | 0.81 | HRH3 (0.66) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL21708843 | 0.80 | APP (0.55) | HRH3KDM4EALDH1A1APP | |
| SCHEMBL14922719 | 0.79 | HRH3 (0.63) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| Hydrochloric Acid SCHEMBL21595634 | 0.79 | SMN1; SMN2 (0.68) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL20912325 | 0.79 | HRH3 (0.63) | HRH3LTA4HKEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2212333-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | HRH3 2715/4885LTA4H 3229/4885KEAP1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.